TransMedics Group, Inc.

government; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028, or the Notes; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreements to which we will remain subject until maturity; the impact of any product recalls or improper use of our products; our international expansion plans and the costs related thereto; and our estimates regarding revenue, expenses, capital expenditures and needs for additional financing.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company believes that its existing cash of $ 472.7 million as of June 30, 2026 will be sufficient to fund its operations, capital expenditures, and debt service payments for at least the next 12 months following the filing of this Quarterly Report on Form 10-Q.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

If the Company needs to seek additional funding through equity financings, debt financings or strategic alliances, the Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of the Company s shareholders.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The carrying value of the Company s long-term debt approximates its fair value (a Level 2 measurement) at each balance sheet date due to its variable interest rate, which approximates a market interest rate.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Company s 1.50 % convertible senior notes due 2028 (the Notes ) are carried at the face value less unamortized debt discount and issuance costs on the accompanying condensed consolidated balance sheets, and the fair value of the Notes is presented at each reporting period for disclosure purposes only (see Note 7).

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

The Notes will mature on June 1, 2028 , unless earlier repurchased, redeemed or converted.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Our consistent performance across all areas of the business reflects the successful execution of our strategy, the differentiated value our OCS and NOP platforms, and our unique leadership position in the transplant market,” said Waleed Hassanein, MD, President and Chief Executive Officer.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

“Looking ahead, we are confident in our strategy and remain laser focused on achieving and surpassing the target of 10,000 US NOP transplants in 2028, while ramping up investments to drive the next several waves of growth aimed at delivering significant top-and bottom-line growth for our business.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

The increase was due primarily to the increase in utilization of the Organ Care System (“OCS”), primarily in Liver and Heart through the National OCS Program ( NOP ) and related NOP service revenue fueled by the continued expansion and utilization of our aviation fleet.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, and statements about our strategy, our focus on achieving and surpassing the target of 10,000 US NOP transplants in 2028, investments to drive waves of growth, and financial and business growth.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans and our objectives for future operations, are forward-looking statements.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

These forward-looking statements are subject to a number of risks and uncertainties.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements.

SEC original ↗TransMedics Group, Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described or referenced in the section titled Risk Factors, which could cause actual results to differ materially.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

Legal Proceedings 34 Item 1A.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026

If the Company needs to seek additional funding through equity financings, debt financings or strategic alliances, the Company may not be able to obtain financing on acceptable terms, or at all, and the terms of any financing may adversely affect the holdings or the rights of the Company s shareholders.

SEC original ↗TransMedics Group, Inc. — 10-Q Quarterly report10-QAug 4, 2026